MDX-33

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMDX-33
Drug Alias NameMDX-33Mab-h22
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionMacrophages inhibitors
TargetsHigh affinity immunoglobulin gamma Fc receptor I
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb CompanyCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCsl Behring LlcBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune +[4] 

Other Information

ATC CodeN/A
Related LinksN/A